Comparison of Days Alive Out of Hospital With Initial Invasive vs Conservative Management: A Prespecified Analysis of the ISCHEMIA Trial.


Journal

JAMA cardiology
ISSN: 2380-6591
Titre abrégé: JAMA Cardiol
Pays: United States
ID NLM: 101676033

Informations de publication

Date de publication:
01 09 2021
Historique:
pubmed: 4 5 2021
medline: 14 1 2022
entrez: 3 5 2021
Statut: ppublish

Résumé

Traditional time-to-event analyses rate events occurring early as more important than later events, even if later events are more severe, eg, death. Days alive out of hospital (DAOH) adds a patient-focused perspective beyond trial end points. To compare DAOH between invasive management and conservative management, including invasive protocol-assigned stays, in the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) randomized clinical trial. In this prespecified analysis of the ISCHEMIA trial, DAOH was compared between 5179 patients with stable coronary disease and moderate or severe ischemia randomized to invasive management or conservative management. Participants were recruited from 320 sites in 37 countries. Stays included overnight stays in hospital or extended care facility (skilled nursing facility, rehabilitation, or nursing home). DAOH was separately analyzed excluding invasive protocol-assigned procedures. Data were collected from July 2012 to June 2019, and data were analyzed from July 2020 to April 2021. Invasive management with angiography and revascularization if feasible or conservative management, with both groups receiving optimal medical therapy. The hypothesis was formulated before data lock in July 2020. The primary end point was mean DAOH per patient between randomization and 4 years. Initial stays for invasive protocol-assigned procedures were prespecified to be excluded. Of 5179 included patients, 1168 (22.6%) were female, and the median (interquartile range) age was 64 (58-70) years. The average DAOH was higher in the conservative management group compared with the invasive management group at 1 month (30.8 vs 28.4 days; P < .001), 1 year (362.2 vs 355.9 days; P < .001), and 2 years (718.4 vs 712.1 days; P = .001). At 4 years, the 2 groups' DAOH were not significantly different (1415.0 vs 1412.2 days; P = .65). In the invasive management group, 2434 of 4002 stays (60.8%) were for protocol-assigned procedures. There were no clear differences at any time point in DAOH when protocol-assigned procedures were excluded from the invasive management group. There were more hospital and extended care stays in the invasive management vs conservative management group during follow-up (4002 vs 1897; P < .001). Excluding protocol-assigned procedures, there were fewer stays in the invasive vs conservative group (1568 vs 1897; P = .001). Cardiovascular stays following the initial assigned procedures were lower in the invasive management group (685 of 4002 [17.1%] vs 1095 of 1897 [57.8%]; P < .001) due to decreased spontaneous myocardial infarction stays (65 [1.6%] vs 123 [6.5%]; P < .001) and unstable angina stays (119 [3.0%] vs 216 [11.4%]; P < .001). DAOH was higher for patients in the conservative management group in the first 2 years but not different at 4 years. DAOH was decreased early in the invasive management group due to protocol-assigned procedures. Hospital stays for myocardial infarction and unstable angina during follow-up were lower in the invasive management group. DAOH provides a patient-focused metric that can be used by clinicians and patients in shared decision-making for management of stable coronary artery disease. ClinicalTrials.gov Identifier: NCT01471522.

Identifiants

pubmed: 33938917
pii: 2779701
doi: 10.1001/jamacardio.2021.1651
pmc: PMC8094032
doi:

Banques de données

ClinicalTrials.gov
['NCT01471522']

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1023-1031

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR001445
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL105565
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL105561
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL105907
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL105462
Pays : United States

Auteurs

Harvey D White (HD)

Green Lane Cardiovascular Services, Auckland City Hospital, University of Auckland, Auckland, New Zealand.

Sean M O'Brien (SM)

Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina.

Karen P Alexander (KP)

Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina.

William E Boden (WE)

VA New England Healthcare System, Boston University School of Medicine, Boston, Massachusetts.

Sripal Bangalore (S)

NYU Grossman School of Medicine, New York, New York.

Jianghao Li (J)

Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina.

Cholenahally N Manjunath (CN)

Sri Jayadeva Institute of Cardiovascular Sciences and Research, Bangalore, India.

Jose Luis Lopez-Sendon (JL)

Hospital Universitario La Paz, Idipaz, Universidad Autonoma de Madrid, Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBER-CV), Madrid, Spain.

Jesus Peteiro (J)

Hospital Universitario A Coruña, Universidad de A Coruña, Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBER-CV), A Coruña, Spain.

Gilbert Gosselin (G)

Montreal Heart Institute, Montreal, Quebec, Canada.

Jeffrey S Berger (JS)

NYU Grossman School of Medicine, New York, New York.

Aldo Pietro Maggioni (AP)

ANMCO Research Center, Florence, Italy.

Harmony R Reynolds (HR)

NYU Grossman School of Medicine, New York, New York.

Judith S Hochman (JS)

NYU Grossman School of Medicine, New York, New York.

David J Maron (DJ)

Department of Medicine, Stanford University, Stanford, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH